<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-032676
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20051026
<FILING-DATE>20051026
<DATE-OF-FILING-DATE-CHANGE>20051026
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>051155509
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v027760_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARIZER HTML 3.0.0.39895 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
        AND EXCHANGE COMMISSION</strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
        D.C. 20549</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
        6-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
        OF
        FOREIGN ISSUER</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to Rule 13a-16 or 15d-16 of</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        Securities Exchange Act of 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
        the month of October 2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
        File Number 000-51122</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
        of registrant&#8217;s name into English)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
        12
        BGC Centre</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
        The
        Esplanade</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
        WA
        6000</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
        of principal executive offices)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
        by check mark whether the registrant files or will file annual reports under
        cover Form&#160;20-F or Form&#160;40-F). </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
        20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
        40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(1):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(7):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark whether the registrant by furnishing the information contained
        in
        this Form is also thereby furnishing the information to the Commission pursuant
        to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        "Yes"
        is marked, indicate below the file number assigned to the registrant in
        connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
        </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the registrant,
        pSivida Limited, has duly caused this report to be signed on its behalf by
        the
        undersigned, thereunto duly authorized. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                October 26, 2005</font></td>
              <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td>&#160;</td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
              <td align="left">
                <hr style="COLOR: #000000" align="left" noshade size="2" width="80%">
              </td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Aaron
                Finlay<br><em>Chief Financial Officer and Company
                Secretary</em></font></td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 207pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
        INDEX</u></em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="15%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                  99.1:</strong></font></div>
              </td>
              <td align="left" valign="top" width="62%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  to ring closing on NASDAQ Stock
                  Market</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
            2
            -</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v027760_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARIZER HTML 3.0.0.39895 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div><br>
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td width="50%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ASX/MEDIA
                  RELEASE</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 161.1pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 0.9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
              </td>
              <td width="50%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><IMG SRC="psivida.jpg"></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font id="TAB1" style="MARGIN-LEFT: 171pt"></font><font id="TAB1" style="MARGIN-LEFT: 18pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>26
        October 2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        to ring closing on NASDAQ Stock Market</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Company
        celebrates nine months on The NASDAQ</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div>
          <hr style="COLOR: #000000" align="left" noshade size="1" width="100%">
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
        bio-nanotech company pSivida Limited </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(ASX:PSD,
        NASDAQ:PSDV, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        is
        pleased to announce that CEO, Mr Gavin Rezos will preside over the NASDAQ
        closing bell ceremony today at the Times Square NASDAQ Market site in New
        York
        city. The event will take place on Wednesday, 26 October 2005 at 4:00pm EDT
        US
        (Thursday, October 27 at 4:00am WST Australia).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        listed on a Level 2 American Depositary Receipt (ADR) programme on the NASDAQ
        National Market in January 2005 in which Citigroup was selected as the
        Depositary Bank to administer the ADR programme. The number of ADR&#8217;s on issue
        has more than quadrupled over this period reflecting the greater visibility
        the
        Company has achieved in the United States, the world&#8217;s largest healthcare and
        investment markets.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        one of
        the first large transactions in the medical nanotech industry, pSivida recently
        announced that it had entered into a US$104 million definitive merger agreement
        to acquire Control Delivery Systems (CDS). CDS is a privately owned US based
        drug delivery company with the potential to create a global bio-nanotech
        company
        specializing in drug delivery, with revenues from existing products and
        generating long-term value through its diversified late-stage product portfolio.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;We
        are
        honored to be ringing the closing bell today at NASDAQ,&#8221; said Mr Rezos. &#8220;Our
        NASDAQ listing, completion of recent successful capital raisings and the
        planned
        acquisition of CDS mark the beginning of a strong growth in business development
        for our company in the US.&#8221;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36.1pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
        view
        pSivida&#8217;s closing ceremony live, please visit the NASDAQ web cam link at
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>http://www.nasdaq.com/reference/marketsite_about.stm</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        Viewers
        are advised to visit the NASDAQ web cam site twenty minutes prior to screening
        and download the webcam in order to have time to troubleshoot technical
        difficulties. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Released
        by:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                  Limited</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                  Leedman</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                  Relations</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  Limited</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  + 61 8 9226 5099</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
              </td>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                  Public Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                  Jedynak</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                  E. Janis &amp; Company, Inc</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +1 (312) 943 1100 ext. 12</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
              </td>
              <td align="left" valign="top" width="28%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                  &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                  Swallow / Helena Podd</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                  Dewe Rogerson</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +44 (0)20 7638 9571</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
        TO EDITORS:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        is a global bio-nanotech company committed to the biomedical sector and the
        development of products in healthcare. The company&#8217;s focus is the development
        and commercialisation of a modified form of silicon (porosified or
        nano-structured silicon) known as BioSilicon&#8482;. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        owns the intellectual property pertaining to BioSilicon&#8482; for use in or on humans
        and animals. The IP portfolio consists of 29 patent families, 34 granted
        patents
        and over 80 patent applications. The core patent, which recognises BioSilicon&#8482;
        as a biomaterial was granted in the UK in 2000 and in the US in 2001.
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
        the
        Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
        and in
        Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
        PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
        pSivida&#8217;s shares also trade in the United Kingdom on the OFEX International
        Market Service (IMS) under the ticker symbol </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        pSivida
        is a founding member of the NASDAQ Health Care Index and the Merrill Lynch
        Nanotechnology Index.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company&#8217;s strategic partner and largest shareholder is the QinetiQ group, the
        largest science and technology company in Europe. QinetiQ is the former UK
        government Defence Evaluation Research Agency and was instrumental in
        discovering BioSilicon&#8482;. pSivida enjoys a strong relationship with QinetiQ
        having access to its cutting edge research and development facilities. For
        more
        information on QinetiQ visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.qinetiq.com</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        more
        information visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
        announcement does not constitute an offer of any securities for sale or the
        solicitation of an offer to buy any securities. Any securities offered may
        not
        be or have not been registered under the US Securities Act of 1933, as amended,
        and may not be offered or sold in the United States absent registration or
        an
        applicable exemption from registration requirements."</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
        document contains forward-looking statements that involve risks and
        uncertainties. Although we believe that the expectations reflected in such
        forward-looking statements are reasonable at this time, we can give no assurance
        that such expectations will prove to be correct. Given these uncertainties,
        readers are cautioned not to place undue reliance on such forward-looking
        statements. Actual results could differ materially from those anticipated
        in
        these forward-looking statements due to many important factors including:
        our
        failure to develop applications for BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        due to
        regulatory, scientific or other issues, our inability to negotiate and
        consummate the proposed acquisition, our inability to successfully integrate
        the
        CDS&#8217;s operations and employees; the failure of the CDS&#8217;s products</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        to
        achieve expected revenues and the combined entity&#8217;s inability to develop
        existing or proposed products. Other reasons are contained in cautionary
        statements in the Registration Statement on Form 20-F filed with the U.S.
        Securities and Exchange Commission, including, without limitation, under
        Item
        3.D, "Risk Factors" therein. We do not undertake to update any oral or written
        forward-looking statements that may be made by or on behalf of
        pSivida.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>psivida.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 psivida.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0H]17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P(#<N,``R,#`U.C$P.C(V(#`P.C,T
M.C0X``````.@`0`#`````?__``"@`@`$`````0```-B@`P`$`````0```#T`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```)#P````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"0`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54DED]2`Q<AF30W8\$.?M$;MSMKVOCZ6Y0<SG]C'[A
MCQ1!''KK&/[R8BS3K*AU'J].%8S&95;EYMK=U6)0W<\MD,]2Q[ME&-3N/\]D
MVU5_VUE]1R\#(OM^Q.+WT6FK*L;NV>J!+J6O_F[+*/\`#^G_`#/\W9^D5Y_Z
MKTAKZ)99>VO<Z23+@-SM57//F.;/CGC`'+Q]R4A.^*)CQPX(^W\W^$GAN(,3
MN:V^U"[%ZGD5/RNLYPP,9C2]^+AOV-8QLO<[)ZB]K<BS:SZ;\?[#7_QG\XB_
M5EN:.EBS+?:X76V68K<C6YF.YQ.)7D/=NL=;Z.U[_5_35[_1L_FU.KI6)D8U
M3;6S4'A]E<`"QU;II]?_`$C*W_I-COSU9ZGU''Z7@79^2'&G';N>&#<Z)V^U
MNGBKF*9GCC(CA,@)<-\5<7];TL9B(DGI'JVDES)_QA?5YK\>3>*LB)R#4?2K
M<0"ZJVW_`$E6YOK^CZWH_P"$6EUC)NKLIH8\TLLU?:/"6CG^1.YR9S.>/+XC
MED"0*%#K*1X8I@8S-1(-.HDL[&HSZ,ENV[[1BO$N<]TG^Q]+_P`@IV?9OVM5
MN=9Z^SVM$>G$6?2_E?23!S)X!*6,XR<D<7#D-?/^ECG'BCD7\/C>EMY)9G3?
MK#@=2S<W!I%E=_3G;+VVM#1R]FZOW.WL_1_]0LK-Z_T3KOU6S\MQRZ>GUN;5
M;;4T,N)#JG_H)W_Z2O<K-,1R1JP1L3_BO4)+#PNJ](Z3]5<7/-MIP*Z6>BZX
M;KW[O;4QS6?2N?\`Z^Q<YUCZUCJ75/J^>F7Y.*RS(`RL=V^DN8^W';2;&C]%
MD4VM%VQ];[:T:1++&(!.YK3^\]^DL?KGUJZ3T2RNC*-EN5:`YF-0S?86DEN^
M/:UON;^_[T7H7UBZ9UZA]N`]TU$"VJQNU["Z=FYNK??M]KF.0I=QQXN&QQ=G
M_]#U58K\K]KYV1B8E0=CX8-5V:7';]HEI^R4M9_.^C_VIL]3]!;^A_26>O76
M;ZP/SSA-Q.G;FY&9:S'=D,$FBNPGULR!_HJFO]+_`(?TD8?LGH'3&5E]6#@8
MK0QI>X-:/[3S[[+/^W+;$S)CADA*$QQ1D*(1Q&]-*ZN9U&G)HIIJN%6UI>6&
MH$23[K'/;#6[G..[VJW7B9N51C-L=4W'8UKFM&XN.GL<_P"C[E2S<O*ZN*WX
M>-=1B-DMR;*CZE@/_<7$>/T3=/Z1GLK_`."Q,I:_3&L9C-K:RQCVM`L-H=N)
MC_26^ZQ9<.3B>=S1R3D83C#ACQ'CR<`C_.2_[GBXV3CN(H;=?^];5=;:V-8W
MAH@+&^NO_B6ZC_Q0_P"J:MM8_P!;Z+\CZM9]./6^ZU]8#*ZVESG'<WZ+&^YR
MUX@"@-`-&+)K"?\`=+Q/7"/_`!L^D\?SPC_-RUWE]V'Z./BYC238QI#B(VF-
MN[U/S5SWU?\`J3TC)Z7T_*ZEB65Y;&EUV.\O8USPX^Z_&/Y^UK-_^F_PWJ+K
M<G$HRF!ES=P'T3P1\'!1<U&<\4HX^`R/3*.+'(?I1DQ\O$@\4M+C$:;^D.76
M'].ZC7C56&RFTB:SVW::_P`K\Y&N_P"7J/\`BS^2U6<7IF)BO]2MI+^SG&2)
M\$5V)2[);E$'U6#:TR8CW?F_VU1Q\EF&,1],0,\,T<7%*<<.*$N*4(SDV3(7
M]*MX'ZV7NZ#]9<[,:#LZQTZRH.;IMMAM._\`ZWZ-+W?\:KF3T_\`9W^+`T$0
M]]-=UFD'=;;7=M=_Q>_T_P"PNEZU]7.E=<%(ZC6ZS[.7&O:]S/I[?4:[TRW<
MUVQBL]2Z=B]3P;,#+:78]P`>UI+3[2'MAS/=])BU+V:APF\FH]0(A_A_,\%]
M8Y_\;7I$>-/_`)[N5WZUNK/4OJCZ9!9ZK2W;QM-F#MV_R5U%OU?Z7;T=O1;:
MB_"K:UC&ESMPV'=6YML^IO8X?25''^HOU=QSC/958;<2P6UVNL>7ES2U];7N
MG^:KV>RG^9_[<2M1PRUJM1#_`,;:74^H/N^M)Z;T/`Q3UBJL/R>J93!^B86M
M]M>R+[7>G=5_A/\`"[/YOU?3I_4%MC>O?6!MMHOM%H%EX`:'N%F3OM:QI<UG
MJ.]^Q;W4_J=T/JF?^T,JNP9!`%AJL?6'@#9^D]-S?\'^C]G^#5CI/U<Z3T:_
M(NZ?4:3DP+&;B6`-+G,;76[VUM;O_-2O1/MS]P2-4)$_0C]U_]'L?K3]C^V8
MD?M+]H;+/3_97\YZ,L]7[3ZGZ#T?4]+9ZG^$_FT'H_\`S2^WU>IZO[9@>G^U
M_5^U3V^S_;_9N_\`""^?TD>C#_E#\OU_E\S]5)+Y5209GZJ27RJDDI^JDE\J
MI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22G__9_^T.^%!H;W1O<VAO
M<"`S+C``.$))300E```````0`````````````````````#A"24T#[0``````
M$`!(`````0`!`$@````!``$X0DE-!"8```````X`````````````/X```#A"
M24T$#0``````!````'@X0DE-!!D```````0````>.$))30/S```````)````
M```````!`#A"24T$"@```````0``.$))32<0```````*``$``````````3A"
M24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@``````
M`0`R`````0!:````!@```````0`U`````0`M````!@```````3A"24T#^```
M````<```_____________________________P/H`````/______________
M______________\#Z`````#_____________________________`^@`````
M_____________________________P/H```X0DE-!`````````(``3A"24T$
M`@``````!``````X0DE-!`@``````!`````!```"0````D``````.$))300>
M```````$`````#A"24T$&@`````#20````8``````````````#T```#8````
M"@!5`&X`=`!I`'0`;`!E`&0`+0`Q`````0`````````````````````````!
M``````````````#8````/0`````````````````````!````````````````
M`````````!`````!````````;G5L;`````(````&8F]U;F1S3V)J8P````$`
M``````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````
M`````$)T;VUL;VYG````/0````!29VAT;&]N9P```-@````&<VQI8V5S5FQ,
M<P````%/8FIC`````0``````!7-L:6-E````$@````=S;&EC94E$;&]N9P``
M```````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E
M3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N=6T````*15-L:6-E
M5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````````4F-T,0````0`
M````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P``
M`#T`````4F=H=&QO;F<```#8`````W5R;%1%6%0````!````````;G5L;%1%
M6%0````!````````37-G951%6%0````!```````&86QT5&%G5$585`````$`
M``````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$`
M``````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A
M=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E
M9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E
M`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO
M;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T
M;&]N9P``````.$))3001```````!`0`X0DE-!!0```````0````".$))300,
M``````DK`````0```(`````D```!@```-@````D/`!@``?_8_^``$$I&248`
M`0(!`$@`2```_^T`#$%D;V)E7T--``+_[@`.061O8F4`9(`````!_]L`A``,
M"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,
M#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``D
M`(`#`2(``A$!`Q$!_]T`!``(_\0!/P```04!`0$!`0$``````````P`!`@0%
M!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%
M!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<E
MDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D
M]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'
M!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q
M)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75
MY?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U5))9/4@,
M7(9DT-V/!#G[1&[<[:]KX^EN4',Y_8Q^X8\401QZZQC^\F(LTZRH=1ZO3A6,
MQF56Y>;:W=5B4-W/+9#/4L>[91C4[C_/9-M5?]M9?4<O`R+[?L3B]]%IJRK&
M[MGJ@2ZEK_YNRRC_``_I_P`S_-V?I%>?^J](:^B667MKW.DDRX#<[55SSYCF
MSXYXP!R\?<E(3OBB8\<."/M_-_A)X;B#$[FMOM0NQ>IY%3\KK.<,#&8TO?BX
M;]C6,;+W.R>HO:W(LVL^F_'^PU_\9_.(OU9;FCI8LRWVN%UMEF*W(UN9CN<3
MB5Y#W;K'6^CM>_U?TU>_T;/YM3JZ5B9&-4VULU!X?97``L=6Z:?7_P!(RM_Z
M38[\]6>I]1Q^EX%V?DAQIQV[GA@W.B=OM;IXJYBF9XXR(X3("7#?%7%_6]+&
M8B))Z1ZMI)<R?\87U>:_'DWBK(B<@U'TJW$`NJMM_P!)5N;Z_H^MZ/\`A%I=
M8R;J[*:&/-++-7VCPEHY_D3N<F<SGCR^(Y9`D"A0ZRD>&*8&,S42#3J)+.QJ
M,^C);MN^T8KQ+G/=)_L?2_\`(*=GV;]K5;G6>OL]K1'IQ%GTOY7TDP<R>`2E
MC.,G)'%PY#7S_I8YQXHY%_#XWI;>269TWZPX'4LW-P:197?TYVR]MK0T<O9N
MK]SM[/T?_4+*S>O]$Z[]5L_+<<NGI];FU6VU-#+B0ZI_Z"=_^DKW*S3$<D:L
M$;$_XKU"2P\+JO2.D_57%SS;:<"NEGHNN&Z]^[VU,<UGTKG_`.OL7.=8^M8Z
MEU3ZOGIE^3BLLR`,K'=OI+F/MQVTFQH_19%-K1=L?6^VM&D2RQB`3N:T_O/?
MI+'ZY]:ND]$LKHRC9;E6@.9C4,WV%I);OCVM;[F_O^]%Z%]8NF=>H?;@/=-1
M`MJL;M>PNG9N;JWW[?:YCD*7<<>+AL<79__0]56*_*_:^=D8F)4'8^&#5=FE
MQV_:):?LE+6?SOH_]J;/4_06_H?TEGKUUF^L#\\X3<3IVYN1F6LQW9#!)HKL
M)];,@?Z*IK_2_P"'])&'[)Z!TQE9?5@X&*T,:7N#6C^T\^^RS_MRVQ,R8X9(
M2A,<49"B$<1O32NKF=1IR:*::KA5M:7EAJ!$D^ZQSVPUNYSCN]JMUXF;E48S
M;'5-QV-:YK1N+CI['/\`H^Y4LW+RNKBM^'C748C9+<FRH^I8#_W%Q'C]$W3^
MD9[*_P#@L3*6OTQK&8S:VLL8]K0+#:';B8_TEONL67#DXGG<T<DY&$XPX8\1
MX\G`(_SDO^YXN-DX[B*&W7_O6U76VMC6-X:("QOKK_XENH_\4/\`JFK;6/\`
M6^B_(^K6?3CUONM?6`RNMI<YQW-^BQON<M>(`H#0#1BR:PG_`'2\3UPC_P`;
M/I/'\\(_S<M=Y?=A^CCXN8TDV,:0XB-IC;N]3\U<]]7_`*D](R>E]/RNI8EE
M>6QI==CO+V-<\./NOQC^?M:S?_IO\-ZBZW)Q*,I@9<W<!]$\$?!P47-1G/%*
M./@,CTRCBQR'Z49,?+Q(/%+2XQ&F_I#EUA_3NHUXU5ALIM(FL]MVFO\`*_.1
MKO\`EZC_`(L_DM5G%Z9B8K_4K:2_LYQDB?!%=B4NR6Y1!]5@VM,F(]WYO]M4
M<?)9AC$?3$#/#-'%Q2G'#BA+BE",Y-DR%_2K>!^ME[N@_67.S&@[.L=.LJ#F
MZ;;8;3O_`.M^C2]W_&JYD]/_`&=_BP-!$/?37=9I!W6VUW;7?\7O]/\`L+I>
MM?5SI77!2.HUNL^SEQKVO<SZ>WU&N],MW-=L8K/4NG8O4\&S`RVEV/<`'M:2
MT^TA[8<SW?28M2]FH<)O)J/4"(?X?S/!?6.?_&UZ1'C3_P">[E=^M;JSU+ZH
M^F06>JTMV\;39@[=O\E=1;]7^EV]';T6VHOPJVM8QI<[<-AW5N;;/J;V.'TE
M1Q_J+]7<<XSV56&W$L%M=KK'EY<TM?6U[I_FJ]GLI_F?^W$K4<,M:K40_P#&
MVEU/J#[OK2>F]#P,4]8JK#\GJF4P?HF%K?;7LB^UWIW5?X3_``NS^;]7TZ?U
M!;8WKWU@;;:+[1:!9>`&A[A9D[[6L:7-9ZCO?L6]U/ZG=#ZIG_M#*KL&00!8
M:K'UAX`V?I/3<W_!_H_9_@U8Z3]7.D]&OR+NGU&DY,"QFXE@#2YS&UUN]M;6
M[_S4KT3[<_<$C5"1/T(_=?_1['ZT_8_MF)'[2_:&RST_V5_.>C+/5^T^I^@]
M'U/2V>I_A/YM!Z/_`,TOM]7J>K^V8'I_M?U?M4]OL_V_V;O_``@OG])'HP_Y
M0_+]?Y?,_522^54D&9^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?
M*J22GZJ27RJDDI__V0`X0DE-!"$``````%4````!`0````\`00!D`&\`8@!E
M`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`
M;P!S`&@`;P!P`"``-P`N`#`````!`#A"24T$!@``````!P`&`````0$`_^$2
M2&AT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN
M/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX*/#]A9&]B
M92UX87`M9FEL=&5R<R!E<V,](D-2(C\^"CQX.GAA<&UE=&$@>&UL;G,Z>#TG
M861O8F4Z;G,Z;65T82\G('@Z>&%P=&L])UA-4"!T;V]L:VET(#(N."XR+3,S
M+"!F<F%M97=O<FL@,2XU)SX*/')D9CI21$8@>&UL;G,Z<F1F/2=H='1P.B\O
M=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C)R!X;6QN<SII
M6#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]I6"\Q+C`O)SX*"B`\<F1F.D1E<V-R
M:7!T:6]N(&%B;W5T/2=U=6ED.CED8S,R9&4R+30U9#DM,3%D82UB,V)E+3DQ
M.30Q86%A9#9E92<*("!X;6QN<SIX87!-33TG:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+VUM+R<^"B`@/'AA<$U-.D1O8W5M96YT240^861O8F4Z9&]C
M:60Z<&AO=&]S:&]P.CED8S,R9&4P+30U9#DM,3%D82UB,V)E+3DQ.30Q86%A
M9#9E93PO>&%P34TZ1&]C=6UE;G1)1#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*
M/"]R9&8Z4D1&/@H\+W@Z>&%P;65T83X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"CP_>'!A8VME="!E;F0])W<G/S[_
M[@`.061O8F4`9$`````!_]L`A``"`@("`@("`@("`P("`@,$`P("`P0%!`0$
M!`0%!@4%!04%!08&!P<(!P<&"0D*"@D)#`P,#`P,#`P,#`P,#`P,`0,#`P4$
M!0D&!@D-"@D*#0\.#@X.#P\,#`P,#`\/#`P,#`P,#PP,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`S_P``1"``]`-@#`1$``A$!`Q$!_]T`!``;_\0!H@``
M``<!`0$!`0``````````!`4#`@8!``<("0H+`0`"`@,!`0$!`0`````````!
M``(#!`4&!P@)"@L0``(!`P,"!`(&!P,$`@8"<P$"`Q$$``4A$C%!408382)Q
M@10RD:$'%;%"(\%2T>$S%F+P)'*"\25#-%.2HK)C<\(U1">3H[,V%U1D=,/2
MX@@F@PD*&!F$E$5&I+16TU4H&O+C\\34Y/1E=865I;7%U>7U9G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<X2%AH>(B8J+C(V.CX*3E)66EYB9FIN<G9Z?DJ.DI:
M:GJ*FJJZRMKJ^A$``@(!`@,%!00%!@0(`P-M`0`"$0,$(1(Q0051$V$B!G&!
MD3*AL?`4P='A(T(54F)R\3,D-$."%I)3):)CLL('<](UXD2#%U23"`D*&!DF
M-D4:)V1T53?RH[/#*"G3X_.$E*2TQ-3D]&5UA96EM<75Y?5&5F9VAI:FML;6
MYO9'5V=WAY>GM\?7Y_<X2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ
M>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#[^8J[%78J[%78J[%6/>:?-GEGR1HE
MYYD\WZ[9>7-"T]>5WJE_,L,*>`Y,15CV4;GL,(!.P:L^?'@@9Y)",1U+YBM?
MSW_-+\WG9/\`G'G\N8U\K,Q1/S<\]^OI^E2CIZFGZ?&!=70[ACP6NQRWPXQ^
MH_`.DCVIJ-9_BF/T_P`^=B/PCS+R_P#.K7?^<G_R&T/RQ^8-U^=&F_F%+J/F
M33=%N/RX3RS::?:W;7S,!#;7"227-?@(!+5[]J&>,0GM5>=N#VED[1T$8YCF
M&2Y`<'``#?0'F_0Q"S(I=>#$`LE:T/<5S&>N"[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%7_]#[^8JIRR+#%),P)6)"[!14D**F@RO+D&.!F>0!
M.W/9(%O/;#\T_*=[=06DLMWI4MRW"W;4+=X$=JTIS-5'TG.`T/\`P3^QM3FC
MAG*>&4S4?%@81)[N+<#XD!RI:+(!>Q]S,=8UK3-`L7U+5KH6EE&RH\Y5GH7-
M%%$!.Y]LZ_MCMG2=D:<ZG5SX,8(!-$[G8;1!/V./CQRR&H[EB/\`RM;R#_U?
MU_Y$3_\`5/.1_P"3J^S?_*4/])D_XAR/R.;^;]S'/,_YG/?:8VG?E?J&A:CY
MTU"1;?2(O,#7UM8J[[!I#;VTCM0]%'&O\PS,[/\`^"/[/ZW40P8M3Q3F1&(X
M)[D[`68@#XN+K-)JX8R<48\7]([?99>-VGY`:/#>6OYD?\Y/^=V_-KS5:R"3
M3='NHS%Y9TR8[B/3M)4%96'3G*K$]2H.^=+VY[1:+L73G/JL@Q8^7>9'N`%D
MGR'W.DTG8$L^03U,O&GW?P1]T>7Q//N?2OEKSIH6O2RV&EVEW9Q:?;"4-<6Q
MMX%B4A0$)V%`=AX9HO9_VTT7;F:6+3PR@QCQ7.!C$BP-B>N[T.73'#&S5/G+
M1='N?^<BOS7T7\T=1!7\E_RHNYA^5=DXH/,&MJ3%/KC`];:`@I:G]L@R#X3O
MVA/!&NIYO+XL9[1U(SG^YQGT?TY?S_</X?F^PLI>A=BKL5=BJ3W7F+0+*8V]
MYK=A:S@T,,US$CCYJS`YI]3[0]FZ6?AYM3BA+NE.(/R)MLCBG(6`?DF<,T-Q
M&LUO*D\+BJ2QL&4CV(J#FTPYH9HB>.0E$\B#8/Q#`@CFAM3U.QT>QN-2U*X%
MK96H#7$Y!(4$A1LH)ZD=LQ>TNTM/V=IY:G4RX,<.9W-60.EGF0F$#,T.:`T/
MS+H?F2.XFT2_6_CM7"7#*KKQ9A4#XU7MF#V)[2=G]M0E/191D$"`:!%$\OJ`
M99,,\?U"D]S>-;L52G7M<TKRQHFK^8]=O%T_1=!LY]0U:^=698;:V0R2R%4#
M,0JJ30`G"!9H->7+'%`SF:C$63Y!YS^6OY[_`)3?G!=:K8_EQYQ@\SW6B0Q3
MZI##!<PF*.9F6-B9XHP:E3TKDI8Y1YAP]%VIIM82,,^(CGL?TAZYD'8(._U'
M3]*M);_5+ZWTVQ@IZ][=2I#$G(A1R=R%%20!4]<0+8SG&`N1`'FA=*U[0M>2
M:70]:L-9CMV"7$EC<Q7"QLPJ`QB9@"1XX2".;''EAD^B0/N-IM@;'8J[%7__
MT?OYBKL5?/OYN6$=U<789"[K:+<0L5U&3@Z5!X+&K6RU"T):GB<^?_\`@M:"
M.?+.Q9&,3&VHE1%_2("6GC8C7JH]95L7:Z"5`>_R_M9E^6NM1ZKY"M;G698V
MCTGU;>\N;HKP$=M\0>1GV`6,BI/A7.X_X%_:1[7]G\7YCURQDXS>]\'TW?\`
M1,1\'%UT1BR$\AS?-GG^_P!%U;S+-J_ER>VN]#U>TL[W3+VSIZ$\4T".LL94
M`$.#6O?KGSQ_P6--CT_M'J(8XB`J&P``LPC>P^UVG9N49=/&<38/(]X?0WY-
M65F?)EI<FUA-RUU<$W!1>9*O0?%2NP&>Y_\``<T>`]@X\O!'C,Y^JAQ;';?G
MLZ_M"1\4B^CS;\P+R37OS'.F7'[W3M#B58[9EN)$+&-9')6U5I`2S`5`[#/.
M/;_62[6]J3I<F^+3Q`$2,DHWPB4C6$2R`F4@+`_A%ER]+'P\'$.9]WZ7K\7E
MJ'S5Y,L-#U&YF71-15_T[:1O<J]Y`7;E;-)<TG6*0;2#8E?A!"G/H+V1'!V9
MA.]D$[G(?XC_`*O^]_TW+IM3I==A&8F!^D\^6X[MNAZT]`M;6VL;:WLK*VBL
M[.SB2"TM($6.***-0J(B*`%50```*`9T*(Q$0`!0"4>9_-'E_P`F:#J/F?S5
MJUOH7E_2$634M6NFX0PHSK&I=MZ59@/IP@$F@UYL\,,#.9J(YEY[9?G_`/DM
MJ'E;5O.UG^9>A3>5-"N%M-5UWZRJP17#()%AJU"SLIJ%4$GL,EX<KJG$CVKI
M98SD&2/"-B;Z]R*_+K\\?RE_-F:]MOR\\]Z;YFO-.427MA`SQ7*1DT$GH3K'
M(4KMR"T]\98Y1YA.C[3TVKL89B1'3K\CNAOSD\R7^AZ!:6FFS/:SZS.T4MS&
M>+K#&O)PI&X+$@5':N>/_P#!B]H]3V5V9#%II&$L\C$R&Q$(BY`'H38%]UN^
M[/PB<R3T>2^2?RI?S?HDFM3:P+#U99([6)8O5),9H6D)9:5/;/)_8O\`X%<O
M:/L\ZV>H\/B)$1P\7T\S(V*WZ?%SM3KO!GP@6F/Y?6GGCRIYN?28]-N[G2DN
M?JVLHBM]5XG83H[46H!#"FY&V;'_`('^C]H?9_MLZ08<D\`GP9:!\*NF2,C4
M;'U"MS':F&JEBRX^*Q?3O]SZ&\V6ND7OE[4[77KLV.D3(HO;H,$**'4@\B&`
M^(`=,^@_:O2Z'5=F9L6OGX>"0''*ZKU"MZ/\5#DZK!*49@Q%ECOY>:7Y0TNU
MU-/*.JMJL$LR->NTHEX.%(45"K2HSGO^!]V7V)H,.:/9.<YHRD.(F0E1HURC
M'HW:N>21'B"DF\M?GW^3?G'S,GDSRQ^8NC:SYJD>XCCT&WF)N2]JK-.H0@;H
M$8D>QST4XY`60Z3#VII<V3PX9`9=W5DOGK\RO(7Y9:?9ZKY_\U:?Y4T_4+CZ
MI8W>H2>FLLW`OP78U/%2<$8F7)OU6LPZ6(EED(@[;L=UCS'^6?YI?E#YMU0>
M:X+O\L]=T75+/6_-5C+PBCLA%+#>RI*R$#T@'^+B0",($HR&V[1ES:?5Z6<N
M/]V8D&0[N1^3Y^_YQ/\`R_\`^<:/)>L^<9_R&_,2X\[:C?V5I'YBMYKZ*\%O
M`DDAA<".WAX\F+"I)RS-.<@.(.I[!T>@P3F=+D,R0+WO]`?5/GG\P_)'Y::*
MWF+S[YFL?*VC"184O+Z3AZDK=(XT%7D8@5XJ":;Y5&)D:#OM3J\6FAQY9"(\
MWQE_SE-^;OY9?FU_SBA^;-U^7OG'3?-<5B-)%];VSD3P_P"Y:SH9;>54E4$]
M"5H>V7X8&.06'FNWNT-/J^S,IPS$JX??]0Z<WF/_`#ZY15\F_FWQ4+77=/K0
M4_X]7R>LYAPO84WAR^\?I?HOYX_,CR'^6FF)K'GWS;IGE33Y6X03:A.L32L*
M56*/=Y"*[A0<Q8Q,N3V.IUF'31XLLA$>;SCRI_SE+_SC[YVU:WT+RY^:NBW>
MK7;^G9V,[RV;3.>B1&ZCB#L>P4DGMDI89CF'#P=N:+/+AAE!)^'WT]]RMVK_
M`/_2^_F*NQ5Y)^96F23/;W2*Q2YMWM7*1ZE,0PJ15+*54`HQW=37Y;9Y-_P2
M>S)93#*`:E`P-#4S-[D>G3SC#K_'`WR-C9SM'.MOU?I?-LGY9W7YOZ/I?Y7Z
MSYRO_)_E6QU>?4?/GE6T!MKO7[1XHQ!:>L:/&BR(3(!]I2-J@$:?_@)=L8]+
MIL_9F<>'J(SXXQD.&1C(`'8T;!C\B'`]I.S):XP]9&+^(#^+N%]R._,/1=+\
MN>96\OZ'8Q:9HNB6%A8Z3IT(I'!;P6T:1QH#795`&>3_`/!?)/M+J">['_N(
MN^[+Q1Q::,("HC8#R?0OY0SP6OY?V]Q<S);V\-Q=/+-(P5542&I).PSW'_@1
MY\>#V9ADRR$8QED))-`#BYDEP->"<U#R>-12R:_YP\P^8K>WG;3[N:1+&X%O
M?R(X!55^*Q:-@>*@T+4WZ9XYBRR[7[=U?:..$SBG*0A+@SR$MP!OIS"0/"`:
M,JWW%T[`CP\48'F/,?I?5VD6AL-+L+-J%[>!$D(:1ARI\5#*SO2O\S$Y]5]D
MZ0Z328L)YQB`=Y'>M]YF4^?\Z1/>729)<4B4QS8,'R]_SFC_`.LP?F[_`-LR
MV_ZCK;+L'UAT?M)_QGY?</O#\TO^<%O^<?\`R%^>MIY^?\Q_TEJVC^4+JR.D
M^6H+R6ULS<ZA%*);J00LKF0+`J@AAMUKMF7J<I@13Q'LIV3AU\<GC61&J%D"
MS>^WN>:^6=,_Y4+_`,YMZ1Y:\LWMQ^C?+WGVVT6WD=_WLFF:G)'"T,K"G.D-
MQQ.VY%<D3XF*SW.%AA_)O;`AC.PF!\)&ON+]WOS`\FIYST9;..9;;4+.3U]/
MN'!*\J49'IOQ8>'38YYG[?>QT?:;0>")"&6!XH2/*ZHQE_1D/D0#O5/M.EU'
M@ROH>;YIL-8\[_E=J$EG+"UM%(_*73[E>=K/3;G&P-*D#JIKXY\V:#MCVA]@
MM2<,XF,2;,)CBQ3_`*42/+^*)O\`G<J=Q+'BU4;_`+7T5Y(_,G2/.-;01G3=
M8C3F^GR-R#J.K1/MR`[BE1^.?0_L3_P1]#[2_N@/"U`%F!-V.IA+;BKJ*!'=
M6[J=3HY8=^8[T1^:/_*!>8_^,,?_`">CS(_X)_\`SC>K_JQ_W<4:+^^C^.CS
M_P#(3_CF>8O^8N'_`)-G.!_X`W^)ZO\`KQ_W)<KM3ZH^Y^3/YJ6Y_P"<?/\`
MG/"V\QQ5L]%NO-%CYC5U'%3I^N'AJ`4#L&DG7Z,^C8?O,5/BNOC_`";VT)C:
M)D)?"7U??(/3/^?G'G&74_.WY:_ES8NTQT;39]8N;9-^5SJ4HM[=:=V"V[4_
MUO?(:2-`ES?;C4\>;'@'07_IC7Z/M?=NN>1H_P`M?^<-/,OD5$X2>7/RPU*V
MO1UK='399+IMOYIF<YC"7%D!\WJLVE_+=DRQ?S<1OW\)O[7PK_SZY_Y2W\V_
M^V/I7_)^?,G6<@\K["?WN7W#[RPW_GY=YEU+4?SF\L>5FG<Z5Y<\LPW-G9D_
MNQ=7]Q-ZTM/%DBC7Y+DM)'TVXWMOGE+5QQ_PQB#\23?W!Z7_`,Y`_P#.'7Y6
M?E?_`,XSW'GSR_\`I2S\\>7M.TEM9U,7DCPZF]Y<VT-PD\#DHJ<I2Z!`M"JU
MKD,6>4LE'DYW:_LYIM)V=XL+$XB-F_JL@&Q^IF/_`#Z[_P"4-_-K_MNZ?_U"
MOD=9S#D^PO\`<Y?>/TJ7YM?\X5_G+^=WY[ZAYV\\><-&B_+ZZU40V=K;7=P]
M_9:#"U(X;:%[7T4E9!5OBIS8L>7=AJ(PC0&Z]H>S6KU^L.3+,>'?0FQ'R%5=
M?:^1_P#G,G\F/R3_`"@U3R?:?E)YI&IWU\MW%YJ\OMJ4>HS6;0>D8)F9/BB,
MG)P5;NM5`WR_3Y)3OB>=]I>S=)HI0_+RLF^(6#7*O=>[]B/^<5_,NK^;_P#G
M'K\J-?UZ[>_U:ZT1(;R]E):28VDLELKNQW9F6(%B=R=\P,PJ9?1^PL\LVAQ3
MD;-?<:_0_P#_T_OYBJ&O;VTTVSN]0U"ZBLK"QA>XO;R=Q'%%%$I=Y'=B`JJH
M))/08L92$0230#XE\@^<OS#_`.<FOS+_`,9^7-6N_)__`#C=Y(N;FPTZ%8PL
M_G2ZH8II)!(IXVJ'[)%"#TI)4QNLT>'-@EAS1$A,41Y?CN>=T.LU':&I&;%(
MPP0.W?D/ZOQS^GO.J?DEH=Y<&YL=8U#3Y:U4.XN`OAQ+T?;W;/&.T_\`@*]G
M:G+XN#49<4O,^)7N)J7SD7M8=HS`H@%\^^=M#D\N>8[W2)-0DU1K9(3]=E!#
ML'C5@""S=*TZY\^^V_8DNQNU<FDEE.8Q$?7+8GBB#WRY77-VNFR>)`2JGH7D
M?\L%\V^7K?4KKS#=6EK)-*GZ.C3D@]-J5!9J5/7[.>A^P_\`P,A[0]EPU.75
MSA`RD/#`L>DU>\JW_JN)J=9X4Z$1?>]O\K_EYH/E5TGM&NKR[C!$<]U*6"<N
MO"->*+7QI7/;/9C_`('O9O8$A/"9SF.4IRNKY\,141[ZOS=;FU4\O.@&=YW3
MC.Q5\O?\YH_^LP?F[_VS+;_J.MLNP?6'1^TG_&?E]P^\/D'_`)];?\<G\YQ7
M<7NB5'_/*\R_6<P\W[!_1F]\?]\^6?S((U#_`)S[N$LR+AF_-#181P-?CBN+
M1'7;NK*0?"F70_N?@Z+7>KMO;?\`>Q^\/W#\]^?D\D+8&32)M1&H>H(I4D6.
M-6CI56)#&M#7IGEGMU[>1]EHXC+!++XET01&(,:V)HF]^Y]GTVE\>]ZI7\OZ
MMHGYC^65FOK&WG24M'J.F2$2>C(I(&]`144(84R_V?[6[/\`;3LD3S8X2!L3
MQGU<$A\B-O5&0H[[(RXYZ?)0/N+Y9:&/0?S`CM_+]RUQ%I^L1QZ?,IY%@9%4
MI4?:ZE3XY\MRPP[)]IQC[/F91QZ@"!!N_4!PWUZP/\[XN[OQ,-SZA]1_FC_R
M@7F/_C#'_P`GH\^H/^"?_P`XWJ_ZL?\`=Q=+HO[Z/XZ//_R$_P".9YB_YBX?
M^39S@?\`@#?XGJ_Z\?\`<ERNU/JC[GPE_P`_/_(7*W_+3\S;6&C1/<^6=7N!
MUHX-Y9;^Q6?[\^B-'+F'RKVYTFV/..GI/WC_`'SY9_*:\U;_`)R<_P"<L/RW
MU#S#$9TMAI,^LQRGFK6OEJPB,A;VGF@J1XR9=D`QXS3H>SIR[5[3QRGTX;_S
M`/OK[7[9?\Y!?^2)_.3_`,`K7?\`J`FS7XOK'O?3NV/\2S?U)?<7YD_\^N?^
M4M_-O_MCZ5_R?GS,UG(/#^PG][E]P^\O+?\`GX]&\/\`SD1;2R*5CE\J:9)&
MQ_:59[I21]((R>D^CXN![:`_GQ_4'Z7Z+_\`.8UU;WG_`#AUYQO+:59;:\TS
M0)K:52"'234+%E(/>H-<Q<']X/B]E[22$NRID<B(_P"ZB\$_Y]=_\H;^;7_;
M=T__`*A7RS6<PZKV%_N<OO'Z7A_GW\YOS;_YR\_/7_E27D7S3)Y'\@76I7EC
M:6]N[0>O9Z>LCW-[?-&RR3%DB9DAY!?LKUJV61QQQ0XCN76:OM/5=L:W\KBE
MP0LCX#F3W\N7P\V'_P#.9'_.-GY=_P#..WEO\K;+RE=7NI^8-?GU,^8]8U"<
M-+<+;I;>F4MTXI$@:1J4%>Q8TR6GRF9-N+[3=BX.S<>(8R3(W9)YU73H_4W_
M`)PQ_P#68?RB_P"V7/\`]1MQF%G^LO>>S?\`QGXO<?O+_]3[^8J^!_SPUG6?
M^<A_S;MO^<6_)VI3:=Y)\OQ0ZQ^?GF2T:CFVY*\&CQN-@TIXEO<^$;J<C&."
M/&>?1Y7M/)/M'4C0XS4([Y"/]S^/T%]PZ!H.C^5]%TOR[Y>TZ#2-$T6VCL]+
MTVW7A%##$O%$4>P'4[GJ=\H))-EZ;%BAB@(0%1`H!-\#8^#?SO\`--G:_FAJ
M'EW2K6X\T>;[R"V>S\I:4%ENRGHI6:X8D1VT*]6EF94`[GIGS)[;>P_:7M![
M2ZB6"(AAB(<>:?IQ0`QQOU?Q$=T;/?3F?RQ@TF*,-YY3=0CO([_[$><J#WK\
MEM`UD^6;2\\QZY:WWHW$WU70M(Y_HZVDYU;E.X62[<';F56/^5/VC['_`,#O
M2:'1]D1P:+*<^.,YCQ".'CE?JX1_,OZ>I&[A9HY\F3CSU$_S1RC[S_$?D.X/
M>,[A+L5=BKY>_P"<T?\`UF#\W?\`MF6W_4=;9=@^L.C]I/\`C/R^X?>'Y6?\
MX=_DIYU_-#1/S*U[\M/S2U3\K_/7E>;3[:PNK262.SO8+Q)VDAN_1(<4,0*L
M`U-_A/49FHR")`(L/`^S79F750R3PY3CG&N7(W?.M^G['UI_SCI_S@;YJ\A_
MF?I_YH_FSYMTW7;_`$&ZEU'2M,TR2YN6N-0DY4NKNYN8X6)1F+@!26:A+;4-
M.74B4:B'H>QO93)IM0,^HF)$&P!9L]Y)`]_O?I!YE\M:;YJTJ72M31C$Y#PS
MIM)%(OV70GN*_2,Y3VD]F])V_HY:74CTG<$?5"0Y2CY_818+WV'-+%+BB^?I
M_P`D/-%K/*NE:[:-;2?#ZK/-`[+X.J*X/WYX!F_X"7;&GR2&DU6,P.UDSA*O
M,1$A]KM1VEC(]43;-_(_Y0P>7;^#6-9O4U*_M3RL[>%2((G[.2V[$=MA3.V]
MB/\`@18NQ=3'6:S(,N6&\8Q%0B?YV^\B.FP`Y[FJQM3KSD'#$4'HOG#1)_,?
MEO5-%MIH[>>_1$CFEKP7C(KFO&IZ+GHGM=V+D[:[*S:+'(1ED``)NA4A+>M^
MCB:?(,<Q(]&-?EOY)OO)5IJEO?7D%XU_-'+&T`8!0BE2#R`SF_\`@<>Q6H]F
M,&;'GR1F<D@1PWM0(WL!NUFI&8@@53%O^<COR?;\\_RE\P_E];7EOINJWLEK
M=Z'J=VK-#;W=K,LBLX0%J,@9#05HV>F8I\$K>?[9[._/Z:6&Z)H@]Q!_5L^=
M?^<1_P#G#K7?^<?/-_F?SAYL\QZ3YBO]2TI-+T5=-CF'H(\PEN6<SHN[>G&!
MQ[5KEN?/X@H.F]GO9N79N262<A(D4*^WF/(/L7\S?*UWYX_+GSWY,L+F&ROO
M->@:CI%G=W`8Q12WEM)"CR!`6XJ7J:;TRB!X9`O1Z[`=1I\F(&C*)'S%/DG_
M`)P__P"<4?-__..>M^==4\R^9]'U^+S/8V=K:QZ8MPK1M;22.Q?UD44(<4IE
MV?,,@%//^SO8&3LR<Y3D)<0'*_U(_P#YR]_YQ'F_YR'/E[S)Y7UNS\O^=_+M
MN]@6U%9#:7MB[F58I'B5WC:)RQ1@K#XF!'0AP9_#V/)E[1>SW\I<,X2$9QVW
MY$?L>#:3_P`X'_G)KWY?WWE?\SOSK?58]&T]K?\`+GR;;WM]/HMC=;"*>Y:5
M$9EB6H2-(]OYJ#CEAU,0;B'5XO9759,!QZC-=#TQ!/"/?[NFSZ5_YQ`_YQP\
MS?\`..>A>==*\R^8-,U^7S/J-K>6DNF+,JQK!"T;*_K*IJ2:BF59\HR%W7L[
MV-D[,A.,Y"7$1R?)GG7_`)][?FEI7YFWWG7\EOS$TO0K&?4YM3T2>\N+RQU'
M3'G9G:-);:&8.J<RH:JDKLPZUNCJH\-2#S^J]D-3'4G+IL@B+L62#'Y`H[SQ
M_P`^[_S+\Z6&EZYK?YV#S;^8]Q+)_B35M>-U):):A1Z$%F:2R_"W(DMQ!KLB
MTW8ZH1Y#9GJ_8[/J(B4\W%DZF5U70#F?QR?H3^0?Y=ZK^4WY0^2?R[UN_M-3
MU/RO:S6US?V(D$$O.YEF4H)0K?9<`U'7,7)+BD2]?V5HY:330PR()C?+WDO_
MU?NEYU\X:+Y"\MWOFKS#=)8Z-ITMK'?7LAXQPK=7,5L)';LJM*"Q[#)1B9&@
MT:G40T^,Y)F@*^T@?I>6_DE^45I^5UU^:WF!]8MM?NOS0\WWGF@:^GVS87*J
M]M;RO4J?19I*%3Q(:NU:"62?%0[@X'9G9XTARSXN+Q)F5^1Y#X;I=^9/_.5O
MY'_EB9++5/.5OK_F.O"U\H^7O]RFHS2G98A'`66-B?\`?C+ACAE+HQUG;NDT
MNQGQ2_FQ]1^SE\:>7Z9?_P#.3O\`SD&WK-;R_P#.,OY73T*R<5N?..HPL*_!
MZ@$=B&_F*<Q7;EDCP0\S]CA0GK^T-_\`%\?_`$L/_$_?[V?:7_SCROEG3+G0
M_*%U8Z%I=]+ZVKW#^O=:EJD__+1J=_,QFN9"=_B/$?LJ,\A]L_9'V@]I"<<]
M7CQ:>]L<1*CW<9_B/RCY=7J.S,.D[/C6.!XCSD=Y$^9>A^4/)GG7RJ+2PC\R
MV,VAQ7'JW-E]6)<JQK(J.34$X/9'V.[>[`&/3QUF*6F$^*4.#>B?4(RYB_L+
MEZC48LMGA-^]ZYGK#@NQ5V*O)?SU_+B]_-S\IO.GY<Z?J<.C7GFFUBMX-3N(
MVEBB,=Q%,2R(0341TV.3QRX9`N!VIHSK--/"#1E6_P`07BO_`#B/_P`XRZW_
M`,XWV?GJUUGS58^9SYMGL)K=[*WDMQ"+-)U8-ZC-7EZHI3PRS/F\2G5^SW8<
MNRQ,2D)<5<O*_P!;[$RAZ-V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O
M_];[5_G7_P`J^_Y51Y[_`.5J_P#DO?T5+_B>G/GZ%1Q]+T_C]3U./I\=^=,G
MCOB%<W![2\'\M/Q_[NM_V>=\O-^,VBK_`,XBBWB-Y-_SD0_D3FW!+B*V71@M
M=N36DC,5I_**YFGQ/*_B^<XOY,K?\QX?GP\/V/TI_P"<<?\`H3OTH?\`E0O^
M%OTUP^+G7]/=/BY_7_\`3/G3X<QLOB?Q/:=C_P`E[?E>'B_V?^R]3[!RAZ!V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
